Trastuzumab biosimilar - Intas Pharmaceuticals
Latest Information Update: 22 Nov 2016
At a glance
- Originator Intas Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 11 Mar 2016 Intas Pharmaceuticals completes a phase III trial in Breast cancer (Metastatic disease) in India (CTRI2015-09-006168)